Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Effect of radiation on the penetration of irinotecan in rat cerebrospinal fluid.

Khatri A, Gaber MW, Brundage RC, Naimark MD, Hanna SK, Stewart CF, Kirstein MN.

Cancer Chemother Pharmacol. 2011 Sep;68(3):721-31. doi: 10.1007/s00280-010-1542-3. Epub 2010 Dec 16.

PMID:
21161529
2.

Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates.

Blaney SM, Takimoto C, Murry DJ, Kuttesch N, McCully C, Cole DE, Godwin K, Balis FM.

Cancer Chemother Pharmacol. 1998;41(6):464-8.

PMID:
9554590
3.

Pharmacokinetic mechanisms for reduced toxicity of irinotecan by coadministered thalidomide.

Yang XX, Hu ZP, Chan SY, Duan W, Ho PC, Boelsterli UA, Ng KY, Chan E, Bian JS, Chen YZ, Huang M, Zhou SF.

Curr Drug Metab. 2006 May;7(4):431-55.

PMID:
16724931
4.

[Influence of genetic polymorphisms in UGT1A1, UGT1A7 and UGT1A9 on the pharmacokynetics of irinotecan, SN-38 and SN-38G].

Valenzuela Jiménez B, González Sales M, Escudero Ortiz V, Martínez Navarro E, Pérez Ruixo C, Rebollo Liceaga J, González Manzano R, Pérez Ruixo JJ.

Farm Hosp. 2013 Mar-Apr;37(2):111-27. doi: 10.7399/FH.2013.37.2.386. Spanish.

5.

[Irinotecan pharmacokinetics].

Chabot GG, Robert J, Lokiec F, Canal P.

Bull Cancer. 1998 Dec;Spec No:11-20. Review. French.

PMID:
9932079
6.

Clinical pharmacokinetics of irinotecan.

Chabot GG.

Clin Pharmacokinet. 1997 Oct;33(4):245-59. Review.

PMID:
9342501
7.

Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors.

Baker SD, Heideman RL, Crom WR, Kuttesch JF, Gajjar A, Stewart CF.

Cancer Chemother Pharmacol. 1996;37(3):195-202.

PMID:
8529278
8.

Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion.

Kurita A, Kado S, Kaneda N, Onoue M, Hashimoto S, Yokokura T.

Cancer Chemother Pharmacol. 2003 Nov;52(5):349-60. Epub 2003 Aug 6.

PMID:
12904895
9.

Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats.

Bansal T, Mishra G, Jaggi M, Khar RK, Talegaonkar S.

Eur J Pharm Sci. 2009 Mar 2;36(4-5):580-90. doi: 10.1016/j.ejps.2008.12.005. Epub 2008 Dec 24.

PMID:
19135530
10.

Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials.

Chabot GG, Abigerges D, Catimel G, Culine S, de Forni M, Extra JM, Mahjoubi M, Hérait P, Armand JP, Bugat R, et al.

Ann Oncol. 1995 Feb;6(2):141-51.

PMID:
7786822
11.

Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide.

Klein CE, Gupta E, Reid JM, Atherton PJ, Sloan JA, Pitot HC, Ratain MJ, Kastrissios H.

Clin Pharmacol Ther. 2002 Dec;72(6):638-47.

PMID:
12496745
12.

Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group.

Thompson PA, Gupta M, Rosner GL, Yu A, Barrett J, Bomgaars L, Bernstein ML, Blaney SM, Mondick J.

Cancer Chemother Pharmacol. 2008 Nov;62(6):1027-37. doi: 10.1007/s00280-008-0692-z. Epub 2008 Feb 16.

PMID:
18278496
13.

Experimental antitumor activity and pharmacokinetics of the camptothecin analog irinotecan (CPT-11) in mice.

Bissery MC, Vrignaud P, Lavelle F, Chabot GG.

Anticancer Drugs. 1996 Jun;7(4):437-60.

PMID:
8826613
14.
15.

Pharmacokinetic modulation of irinotecan metabolites by sulphobromophthalein in rats.

Itoh T, Itagaki S, Sasaki K, Hirano T, Takemoto I, Iseki K.

J Pharm Pharmacol. 2004 Jun;56(6):809-12.

PMID:
15231047
16.

Non-linear pharmacokinetics of irinotecan in mice.

Rouits E, Guichard S, Canal P, Chatelut E.

Anticancer Drugs. 2002 Jul;13(6):631-5.

PMID:
12172509
17.

Allometric scaling of a metabolically complex camptothecin analog: differences in scaling of irinotecan and its active metabolite, SN-38.

Ahlawat P, Srinivas NR.

Arzneimittelforschung. 2009;59(6):311-7. doi: 10.1055/s-0031-1296402.

PMID:
19634513
18.

Phase I study of irinotecan in pediatric patients with malignant solid tumors.

Mugishima H, Matsunaga T, Yagi K, Asami K, Mimaya J, Suita S, Kishimoto T, Sawada T, Tsuchida Y, Kaneko M.

J Pediatr Hematol Oncol. 2002 Feb;24(2):94-100.

PMID:
11990713
19.

Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan.

Ma MK, Zamboni WC, Radomski KM, Furman WL, Santana VM, Houghton PJ, Hanna SK, Smith AK, Stewart CF.

Clin Cancer Res. 2000 Mar;6(3):813-9.

20.

Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation.

Allegrini G, Di Paolo A, Cerri E, Cupini S, Amatori F, Masi G, Danesi R, Marcucci L, Bocci G, Del Tacca M, Falcone A.

Cancer Chemother Pharmacol. 2006 Nov;58(5):585-93. Epub 2006 May 6.

PMID:
16680463

Supplemental Content

Support Center